Evidence map›Paper›PMID 41307678›Full record

ArticleAnnals of hematology2025

Length of hospital stay and outcome in primary central nervous system lymphoma: a French retrospective multicentric study.

Raphaël Maguet, Martin Eloit, Olivier Chinot, Pierre Soubeyran, Carole Soussain, Roch Houot, Guido Ahle, Vincent Delwail, Aline Clavert, Lucie Oberic and 6 more

Abstract readMulticenter Study
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Raphaël MaguetService d'hématologie Et Thérapie Cellulaire, Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, 2 Boulevard Tonnellé, 37000, Tours, France.
Martin EloitService d'hématologie Et Thérapie Cellulaire, Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, 2 Boulevard Tonnellé, 37000, Tours, France.
Olivier ChinotService de Neuro-Oncologie, CHU de La Timone, Marseille, France.
Pierre SoubeyranService d'hématologie, Institut Bergonié, Bordeaux, France.
Carole SoussainService d'hématologie, Institut Curie, Saint Cloud, France.
Roch HouotService d'hématologie, CHU de Rennes, Rennes, France.
Guido AhleService de Neurologie, Hôpital Civil de Colmar, Colmar, France.
Vincent DelwailService d'hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
Aline ClavertService des Maladies du Sang, Centre Hospitalier Universitaire d'Angers, Angers, France.
Lucie ObericService d'hématologie, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
Renata UrsuService de Neurologie, Hôpital Saint Louis, Paris, France.
Hélène SellenartService d'oncologie, Institut de Cancérologie de l'Ouest, Saint Herblain, France.
Julie AbrahamService d'hématologie, Centre Hospitalier Universitaire de Limoges, Limoges, France.
Olivier HeraultService d'hématologie Biologique, Centre Hospitalier Universitaire de Tours, Tours, France.
Caroline HouillierService de Neuro-Oncologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Emmanuel GyanService d'hématologie Et Thérapie Cellulaire, Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, 2 Boulevard Tonnellé, 37000, Tours, France. emmanuel.gyan@univ-tours.fr.ORCID http://orcid.org/0000-0002-7651-9189

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare form of lymphoma with a poor prognosis. We used the LOC network database, including 365 patients from 14 voluntary centers. Inclusion criteria were age ≥ 60 years, immunocompetence, confirmed PCNSL diagnosis and treatment with curative intent with MPV-based regimen (Methotrexate, Procarbazine, Vincristine) between 2011 and 2021. We analyzed LOS from first day of chemotherapy to dismissal from hospital. Using the MAXStat method we found the LOS threshold of 15 days, to be one of most statistically significant and most convenient to separate two groups with different OS. The median age of the whole population was 71 years, median Karnofsky performance score (KPS) was 70%. The main differences between short and long LOS groups were median KPS at diagnosis (70% vs 50%) and deep structure involvement status (51% vs 67%). With a median follow up of 22.8 months, the median OS was respectively 62.2 and 20 months for short and long LOS. Median PFS was respectively 18 and 9.3 months. Multivariate analysis found in our cohort that age was associated with OS (P = 0.01) and LOS with OS (P = 0.005) and PFS (P = 0.014). KPS at diagnosis is a cofounder to LOS in the analysis. LOS remains associated with OS (P = 0.016) in a subgroup analysis of patients with baseline KPS < 70%. Altogether, the LOS > 15 days identifies a population of patients with poorer outcome in elderly PCNSL patients. Its underlying drivers require further investigation in larger and prospective cohorts.

Indexed as

Central Nervous System NeoplasmsLength of StayLymphomaAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleFranceHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeVincristineVincristineChemotherapyLength of stayPCNSLPrognosis

Identifiers

PMID41307678
PMCPMC12764697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.